Brief: Regenxbio Announces Positive Topline Results From Pivotal Phase Iii Affinity Duchenne® Study Of Rgx-202
14/05/2026 12:03
Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE III AFFINITY DUCHENNE® STUDY OF RGX-202 REGENXBIO INC - PLANS POTENTIAL COMMERCIAL LAUNCH OF RGX-202 IN 2027 REGENXBIO INC - PHASE III STUDY ACHIEVES PRIMARY ENDPOINT WITH 93% OF PATIENTS ABOVE 10% MICRODYSTROPHIN EXPRESSION REGENXBIO INC - RGX-202 SHOWS SIGNIFICANT CORRELATION BETWEEN MICRODYSTROPHIN EXPRESSION AND FUNCTIONAL IMPROVEMENT REGENXBIO INC - RGX-202 DEMONSTRATES WELL-TOLERATED, DIFFERENTIATED SAFETY PROFILE REGENXBIO INC - PREPARING FOR POTENTIAL ACCELERATED APPROVAL OF RGX-202 IN 2027 REGENXBIO INC - TWO SERIOUS ADVERSE EVENTS REPORTED, BOTH RESOLVED WITHOUT SEQUELAE REGENXBIO INC - RGX-202 SHOWS FAVORABLE SAFETY PROFILE WITH >80% FULL CAPSID PURITY Source text: ID:nPn3nHF0Qa Further company coverage: RGNX.O